pomalidomide has been researched along with Venous Thrombosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
| Hunt, BJ; Jones, R; Parmar, K; Schey, S; Streetly, M; Zeldis, J | 1 |
1 trial(s) available for pomalidomide and Venous Thrombosis
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
1 other study(ies) available for pomalidomide and Venous Thrombosis
| Article | Year |
|---|---|
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Humans; Immunologic Factors; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transforming Growth Factor beta; Transforming Growth Factor beta2; Vascular Endothelial Growth Factor A; Venous Thrombosis | 2005 |